Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase IIa study of LAB's GHRH completes enrollment

Feb. 13, 2007

Critical Biologics closes Series A financing in support of rhu-pGSN development

Feb. 13, 2007

Amgen warns medical community on off-label use of Aranesp

Feb. 12, 2007

SP-6300 shows potential for Cushing's syndrome

Feb. 9, 2007

Sciele Pharma licenses fenofibrate/pravastatin combination for mixed dyslipidemia

Feb. 9, 2007

Chinese clinical trials confirm XiMingTing's utility in menopausal symptoms

Feb. 9, 2007

Novel vanadium complex shows insulin mimetic properties in vivo

Feb. 9, 2007

Kuros begins phase II bone regeneration study

Feb. 8, 2007

First pivotal obesity study of lorcaserin completes enrollment

Feb. 7, 2007

Phase III Prochieve study for prevention of preterm birth fails to meet endpoints

Feb. 7, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...